Arthritis & Rheumatology最新文献

{"title":"Journal Club","authors":"","doi":"10.1002/art.43252","DOIUrl":"https://doi.org/10.1002/art.43252","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"77 6","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.43252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Connections","authors":"","doi":"10.1002/art.43253","DOIUrl":"https://doi.org/10.1002/art.43253","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"77 6","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.43253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Connections","authors":"","doi":"10.1002/art.43253","DOIUrl":"https://doi.org/10.1002/art.43253","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"77 6","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.43253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journal Club","authors":"","doi":"10.1002/art.43252","DOIUrl":"https://doi.org/10.1002/art.43252","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"77 6","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.43252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Pain Sensitization after DMARD therapy are Associated with Changes in Disease Activity in Established Rheumatoid Arthritis.","authors":"Burcu Aydemir, Andrew C Heisler, Lutfiyya N Muhammad, Jing Song, Alyssa Wohlfahrt, Daniel J Clauw, Wendy Marder, Marcy B Bolster, Clifton O Bingham, Tuhina Neogi, Yvonne C Lee","doi":"10.1002/art.43265","DOIUrl":"https://doi.org/10.1002/art.43265","url":null,"abstract":"<p><strong>Objective: </strong>Abnormalities in pain regulatory mechanisms are common in patients with rheumatoid arthritis (RA). We investigated whether pain sensitization changes after treatment with a disease modifying anti-rheumatic drug (DMARD) and explored associations between changes in pain sensitization and disease activity.</p><p><strong>Methods: </strong>We included 182 participants with active RA initiating/switching DMARD therapy who were followed for 12 weeks. To assess pain sensitization, participants underwent quantitative sensory testing (QST), including pressure pain thresholds (PPTs) at multiple anatomic sites, temporal summation (TS) at the wrist and forearm, and conditioned pain modulation (CPM). RA disease activity was measured using the Disease Activity Score 28 with C-reactive protein (DAS28-CRP) and its components. Mean changes in QST measures were examined from baseline to 12-weeks, and associations between QST and disease activity measures were explored using Pearson's correlation coefficients and adjusted linear regression analyses.</p><p><strong>Results: </strong>PPTs significantly increased (improved) at multiple anatomic sites following 12-weeks of DMARD therapy. No significant changes were observed in TS or CPM. Increased PPTs at multiple anatomic sites were associated with reductions in DAS28-CRP, swollen joint count, tender joint count, and improvements in patient global assessment. No significant associations were observed between TS, CPM, and disease activity.</p><p><strong>Conclusion: </strong>Pain sensitivity improved following 12 weeks of DMARD therapy. These improvements were associated with reductions in disease activity.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144155364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2024 Vasculitis Foundation Quality Care Summit: Seeking Strategies to Improve Care for All Patients.","authors":"Jason Springer, Elizabeth Brant, Anisha Dua, Jason Wadler, Dahlia Mak, Peter Merkel, Beth Westbrook, Joyce Kullman, Kevin Byram","doi":"10.1002/art.43248","DOIUrl":"https://doi.org/10.1002/art.43248","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144155366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood gene expression profiling shows prognostic significance for the course of interstitial lung disease in systemic sclerosis.","authors":"Shervin Assassi,Christopher P Denton,Matthias Zwick,Ramona Schmid,Carina Ittrich,Tobias Litzenburger,Sudha Visvanathan","doi":"10.1002/art.43262","DOIUrl":"https://doi.org/10.1002/art.43262","url":null,"abstract":"OBJECTIVEWe used data from the placebo arm of the SENSCIS trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without mycophenolate mofetil (MMF) treatment.METHODSPatients had SSc-ILD with first non-Raynaud symptom within ≤7 years. MMF treatment was permitted if taken at a stable dose for ≥6 months. PBC RNA samples were taken at baseline. Global RNA sequencing was performed, followed by a modular analysis using 62 curated whole blood modules. The prognostic significance of baseline composite modular scores for decline in FVC % predicted at week 52 was analyzed using mixed models for repeated measures.RESULTSAmong patients taking MMF (n=120), higher baseline lymphoid lineage and mitochondrial/protein synthesis modules were associated with a better course of FVC % predicted, while higher baseline myeloid lineage and inflammation modules were associated with a faster decline in FVC % predicted. Among patients not taking MMF (n=118), only myeloid lineage and inflammation modules were associated with a faster decline in FVC % predicted.CONCLUSIONAmong patients with SSc-ILD in the SENSCIS trial, PBC modules involved in myeloid lineage were associated with a faster decline in FVC regardless of MMF treatment. Higher baseline lymphoid, protein synthesis and mitochondrial module scores were associated with a better course of SSc-ILD among patients on MMF treatment. Blood gene expression profiles might be useful prognostic/predictive biomarkers in patients with SSc-ILD.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"51 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response.","authors":"Chuan Fu Yap,Nisha Nair,Ann W Morgan,John D Isaacs,Anthony G Wilson,Kimme Hyrich,Guillermo Barturen,María Riva-Torrubia,Marta Gut,Ivo Gut,Marta E Alarcón Riquelme,Anne Barton,Darren Plant","doi":"10.1002/art.43255","DOIUrl":"https://doi.org/10.1002/art.43255","url":null,"abstract":"OBJECTIVESTumor necrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to non-response or adverse effects. This study aimed to identify biomarkers predictive of adalimumab treatment response using whole blood transcriptomics, leveraging machine learning models for data mining followed by targeted statistical analysis.METHODSA cohort of RA patients starting TNFi therapy (n=100) was assessed for treatment response at 6 months, with RNA sequencing performed on baseline (pre-treatment) and 3-month follow-up samples. Machine learning classifiers were built to identify predictive biomarkers for treatment outcomes. This was followed by a network analysis on the biomarkers to elucidate the most influential biomarker, which was subsequently confirmed through survival analysis.RESULTSDifferential gene expression analysis in 97 samples passing QC identified 84 genes associated with treatment response. Random Forest classifiers achieved high predictive accuracy with AUCs up to 0.86, identifying genes contributing to treatment outcomes. Network analysis further elucidated gene interactions, highlighting MZB1 as a novel biomarker not captured by machine learning alone. MZB1's role in B cell development and antibody production was associated with anti-drug antibody formation, impacting treatment efficacy.CONCLUSIONThis study advances the understanding of transcriptomic alterations in RA treatment and enhancing our understanding of treatment response mechanisms. Whilst the gene signatures identified require independent replication, the study serves as a starting point to pave the way for personalized therapeutic strategies in patients commencing TNFi therapy in RA.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"58 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations.","authors":"Chio Yokose,Natalie McCormick,Na Lu,Bohang Jiang,Kiara Tan,Saiajay Chigurupati,Sharan Rai,Greg Challener,J Antonio Aviña-Zubieta,Edoardo Cipolletta,Abhishek Abhishek,Angelo Gaffo,James L Januzzi,Yuqing Zhang,Hyon K Choi","doi":"10.1002/art.43259","DOIUrl":"https://doi.org/10.1002/art.43259","url":null,"abstract":"OBJECTIVEAmong patients with gout, NSAIDs are commonly used despite scarce safety data in this specific population. Therefore, we quantified the comparative cardiovascular safety of NSAIDs versus colchicine among patients with gout starting allopurinol.METHODSWe conducted a sequential, propensity score-matched, new-user comparative effectiveness study using the target trial emulation framework to compare the risk of MACE (composite of myocardial infarction [MI], stroke, or cardiovascular death) among patients with gout started on allopurinol who were prescribed NSAIDs or colchicine for gout flare prophylaxis. A sensivity analysis employed inverse probability of treatment weighting (IPTW). Secondarily, we examined the risk of MACE with colchicine or NSAIDs versus no prophylaxis.RESULTSAmong 18,120 propensity score-matched adults with gout starting allopurinol with NSAIDs or colchicine (83.5% male, mean age 60.9 years), the incidence of MACE and cardiovascular death were higher among NSAID users compared to colchicine users, with rate differences of 38.8 (95% CI, 15.4 to 62.2) and 10.9 (0.7 to 21.1) per 1000 person-years, respectively, and hazard ratios (HR) of 1.56 (1.11 to 2.17) and 2.50 (1.14 to 5.26), respectively. Results were similar when IPTW was applied. Compared to no prophylaxis, NSAID use was associated with a higher risk of MACE and MI with HRs 1.50 (1.17 to 1.91) and 1.93 (1.35 to 2.75), respectively.CONCLUSIONIn these target trial emulations of patients with gout starting allopurinol, NSAID prophylaxis was associated with a higher risk of MACE than colchicine or no prophylaxis, suggesting the avoidance of NSAID for gout flare prophylaxis.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"23 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Interleukin-1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria.","authors":"Remco G A Erkens,Greta Rogani,Laura Huber,Anouk Verwoerd,Dieneke Schonenberg-Meinema,J Merlijn van den Berg,Wineke Armbrust,G Elizabeth Legger,Sylvia Kamphuis,Ellen J H Schatorjé,Esther P A H Hoppenreijs,Joost F Swart,Marc H A Jansen,Jorg van Loosdregt,Sebastiaan J Vastert","doi":"10.1002/art.43263","DOIUrl":"https://doi.org/10.1002/art.43263","url":null,"abstract":"OBJECTIVETo evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA-SD) treated with IL-1-targeted therapy and to assess the incidence of MAS in this context.METHODSWe analyzed retrospective and prospective data from Dutch sJIA-SD patients (diagnosis 2008-2017, n=54) and data from a nationwide prospective Dutch cohort and intervention study (diagnosis 2017-2022, n=66). From these cohorts, MAS episodes developing in sJIA-SD patients treated with IL-1-targeted therapy (anakinra or canakinumab) with at least two year follow-up were selected. Clinical and laboratory data was extracted from the electronic patient files.RESULTSA total of 22 patients experienced 29 MAS episodes while on IL-1-targeted treatment. 7 patients had recurrent MAS episodes (not all on IL-1 blockade). The 2016 criteria for MAS in sJIA-SD were met for 28/29 MAS episodes (97%). Within the prospective nationwide cohort, starting anakinra as first-line monotherapy, the incidence rate of MAS in the first two years of disease was 18% (12/66 patients, with 11/12 while on IL-1 inhibition). This incidence is comparable to that observed in historical corticosteroid-treated patients. Half of MAS episodes occurred within 3 months after diagnosis and Epstein-Barr virus was the most common identifiable trigger.CONCLUSIONWhile first-line anakinra in new-onset sJIA-SD has demonstrated high response rates, our data suggests the incidence of MAS in the first two years of disease is not reduced. Patients appear to be particularly at risk early in disease. Importantly, our data shows that the EULAR/ACR/PRINTO 2016 MAS classification criteria remain applicable to patients receiving IL-1-targeted therapy.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"35 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144146038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}